Today, the subscription period in FluoGuide A/S’s ("FluoGuide" or "Company")
issue of units prior to planned listing at Spotlight Stock Market commences. A
fully subscribed issue of units initially provides the company approx. DKK
15.9 million before issue costs and an additional approx. DKK 6.4 million
before issue costs if all consideration free warrants are utilized. FluoGuide
has secured approximately DKK 9.9 million, corresponding to approx. 62 percent
of the initial issue volume through subscription commitments. The capital is
intended to finance clinical proof-of-concept for the company’s first product
– FG001 – which is lighting up cancer during surgery. Prospectus, teaser and
subscription form are available on the websites of FluoGuide
(www.fluoguide.com), Sedermera Fondkommission (www.sedermera.se) and Spotlight
Stock Market (www.spotlightstockmarket.com). Subscription of shares can be
made by submitting a subscription form to Sedermera Fondkommission or through
Sedermera Fondkommission’s website (via BankID) or Nordnet Bank
(www.nordnet.se or www.nordnet.dk). For subscription of shares directly
through other banks, the subscriber is asked to contact his or her bank.
FluoGuide – intelligent surgical targeting
FluoGuide A/S develops surgical solutions that are expected to reduce
suffering for the patient and increase the likelihood of cure as well as
reduce costs for the health care system. The first product is the compound
FG001, which lights up the cancer and its invasive growth into the surrounding
tissue, and the first indication is glioblastoma (brain tumor). Today, local
cancer tissue is left behind in up to 50 % of patients undergoing surgery with
the intention to completely remove the cancer. In a recently performed non
-human preclinical study on eight subjects, additional local metastases were
found in four of the eight subjects using FG001 and fluorescent light. This
means that in half of the subjects (50 %) traditional white light surgery
overlooked cancer tissue that could be seen and removed with FG001. These
results demonstrate the potential of FG001 to vastly improve the likelihood of
performing radical surgery (removal of all cancer) and thereby improving
outcome and survival.
Morten Albrechtsen, CEO of FluoGuide, comments:
"Imagine that a surgeon simply could inject a compound and turn on a special
light making the tumor clearly visible and fluorescent – allowing the surgeon
to remove the entire cancer. This might sound unreal, but this is what
FluoGuide makes possible. The route to approval of our first product is well
defined and associated with low risk compared to regular drug development. We
plan to establish compassionate use sales as early as in 2020 and market
launch in a first country in 2022/2023. Join us in transforming cancer
surgery!" Offering in summary
Subscription period: April 1st – April 15th, 2019.
Subscription price: DKK 14.85 per unit. One (1) unit consists of three (3)
shares and one (1) consideration free
warrant of series TO 1. The price per share is thus DKK 4.95.
Subscription post: The minimum subscription is 250 units, corresponding to DKK
Issue volume and minimum limit for implementation: The offering comprises a
total of 3,224,274 shares and
1,074,758 warrants of series TO 1, initially corresponding to DKK
15,960,156.30 at the most. The minimum limit
to implement the issue of units is 864,648 units, corresponding to DKK
Number of shares before new share issue: 4,000,000 shares.
Valuation (pre-money): Approximately DKK 19.8 million.
Subscription commitments: The Company has received subscription commitments of
approximately DKK 9.9
million, a total of approximately 62 percent of the issue volume.
· Listing on Spotlight Stock Market: The share in FluoGuide is planned to be
listed on Spotlight Stock Market.The trading is planned to commence on May
Summary of the consideration free warrants
· Exercise period: April 16th – May 7th, 2020.
Exercise price: Each warrant entitles the holder the right to subscribe for
one (1) new share in FluoGuide at a subscription price of DKK 5.95 per share.
Issue volume: If the initial issue of units is fully subscribed, a total of
1,074,758 warrants of series TO 1 will be issued. The warrants can provide the
Company a total of DKK 6,394,810.10 if all warrants are exercised.
Valuation (pre-money): Approximately MDKK 43.0.
Information concerning the news above is also available in Swedish and Danish. Please contact either of the parties below to be provided such information.
Financial advisor, legal advisor and Selling Agent
Sedermera Fondkommission is acting as financial advisor and issuing agency to FluoGuide in connection with the IPO and the planned listing at Spotlight Stock Market. Legal advisor is Markets & Corporate Law. Nordnet Bank AB is acting as Selling Agent in the IPO.
For further information about the IPO and the listing, please contact:
Sedermera Fondkommission Telephone: +46 (0) 40-615 14 10
For further information about FluoGuide, please contact:
Morten Albrechtsen, CEO, FluoGuide A/S Telephone: +45 24 25 62 66
FluoGuide A/S develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Preclinical studies have demonstrated the potential of FG001 to vastly improve the likelihood of performing radical surgery (removal of all cancer) and thereby improving outcome and survival. FluoGuide is initially focused on glioblastoma (brain tumor) but the Company plan to expand its business to other solid tumors. Market launch of FG001 in a first country is expected in 2022/2023.
M: +45 24 25 62 66
Se fullständiga pressmeddelande och andra nyheter från detta bolag hos Cision News